© Website designed by Alasdair Coles, 2012
Current funders: Medical Research Council, Wellcome Trust, MS Society, Moulton
Charitable Trust, Freemason’s Grand Charity.
Clinical investigation of patients treated using alemtuzumab
Orla Tuohy, Grant Cawthorne-Hill, Tom Button, with Michael Fahey [Australia] and
David Miller [UCL]
We continue to follow up all patients treated using alemtuzumab, since 1991.
We have recently published the follow-up of the people with progressive
multiple sclerosis treated between 1991 and 1998.
We are now writing up the long-term follow-up of our relapsing-remitting
cohort, treated since 1999.
We have just published a small study of MTR MRI imaging on people after
alemtuzumab, showing recovery of MTR signal.
We have started a trial of a licensed drug (human KGF) to prevent
autoimmunity after alemtuzumab. More information here.
Immunological studies of alemtuzumab
Joanne Jones, Sara Thompson
We are trying to answer three questions:
Why do people get autoimmunnity after alemtuzumab?
Following on from Amanda Cox and Sara Thompson’s previous work, we have
shown that the reconstitution of T lymphocytes occurs by expansion of
peripheral T cells with reduced thymmic output.
Can we predict who is at risk of autoimmunity after alemtuzumab?
Following Jo Jones’ initial description of the role of IL-21 in autoimmunity
after alemtuzumab we are now refining this into a potential predictive
biomarker for autoimmunity.
Reducing the immunogenicity of alemtuzumab
Alasdair Coles, Jen Sommerfield with Herman Waldmann & Geoff Hale
People treated with alemtuzumab can develop antibodies to the drug which,
rarely, can neutralise the efficacy of subsequent treatments. Following
seminal work in Herman Waldmann’s lab, we performed a trial of pretreating
patients with a variant of alemtuzumab designed to induce long-lasting
tolerance to regular alemttuzumab.